$0.29 EPS Expected for Anika Therapeutics, Inc. (ANIK); Microsemi (MSCC) Had 0 Bulls

Microsemi Corporation (NASDAQ:MSCC) Logo

Among 11 analysts covering Microsemi (NASDAQ:MSCC), 0 have Buy rating, 0 Sell and 11 Hold. Therefore 0 are positive. Microsemi had 19 analyst reports since January 24, 2018 according to SRatingsIntel. Mizuho downgraded the stock to “Hold” rating in Monday, March 5 report. The stock of Microsemi Corporation (NASDAQ:MSCC) has “Buy” rating given on Thursday, January 25 by KeyBanc Capital Markets. PiperJaffray downgraded the stock to “Neutral” rating in Tuesday, March 6 report. The rating was maintained by Mizuho on Friday, January 26 with “Buy”. The firm has “Sector Perform” rating given on Friday, March 2 by RBC Capital Markets. The firm earned “Market Perform” rating on Monday, March 5 by BMO Capital Markets. KeyBanc Capital Markets downgraded Microsemi Corporation (NASDAQ:MSCC) on Monday, March 5 to “Equal-Weight” rating. The rating was maintained by Stifel Nicolaus with “Buy” on Friday, January 26. On Wednesday, January 24 the stock rating was maintained by Susquehanna with “Buy”. The firm has “Hold” rating given on Friday, March 2 by Stifel Nicolaus. See Microsemi Corporation (NASDAQ:MSCC) latest ratings:

30/05/2018 Broker: Stifel Nicolaus Old Rating: Hold New Rating: Hold Terminates
06/03/2018 Broker: PiperJaffray Old Rating: Overweight New Rating: Neutral Downgrade
05/03/2018 Broker: BMO Capital Markets Old Rating: Outperform New Rating: Market Perform Downgrade
05/03/2018 Broker: Mizuho Rating: Hold Downgrade
05/03/2018 Broker: KeyBanc Capital Markets Old Rating: Overweight New Rating: Equal-Weight Old Target: $61 Downgrade
02/03/2018 Broker: Susquehanna Rating: Hold New Target: $69.0 Downgrade
02/03/2018 Broker: SunTrust Rating: Hold New Target: $68.78 Downgrade
02/03/2018 Broker: Deutsche Bank Old Rating: Buy New Rating: Hold Old Target: $60 Downgrade
02/03/2018 Broker: RBC Capital Markets Old Rating: Outperform New Rating: Sector Perform Old Target: $58 Downgrade
02/03/2018 Broker: Needham Old Rating: Buy New Rating: Hold Downgrade

Analysts expect Anika Therapeutics, Inc. (NASDAQ:ANIK) to report $0.29 EPS on July, 25.They anticipate $0.47 EPS change or 61.84% from last quarter’s $0.76 EPS. ANIK’s profit would be $4.15 million giving it 26.96 P/E if the $0.29 EPS is correct. After having $0.11 EPS previously, Anika Therapeutics, Inc.’s analysts see 163.64% EPS growth. The stock decreased 0.70% or $0.22 during the last trading session, reaching $31.27. About 191,685 shares traded. Anika Therapeutics, Inc. (NASDAQ:ANIK) has declined 13.22% since June 29, 2017 and is downtrending. It has underperformed by 25.79% the S&P500. Some Historical ANIK News: 05/03/2018 – JOSEPH DARLING NAMED CEO & DIRECTOR OF ANIKA THERAPEUTICS; 22/03/2018 – Anika at Non-Deal Roadshow Hosted By First Analysis Today; 23/05/2018 – ANIKA THERAPEUTICS INC – PLANS TO UTILIZE EXISTING CASH ON HAND TO FUND ASR PROGRAM; 02/05/2018 – Anika Therapeutics 1Q Loss/Shr 46c; 23/05/2018 – Anika Therapeutics Announces $30 Million Accelerated Share Repurchase; 02/05/2018 – Anika Therapeutics 1Q Rev $21.3M; 19/04/2018 – DJ Anika Therapeutics Inc, Inst Holders, 1Q 2018 (ANIK); 05/03/2018 – ANIKA THERAPEUTICS NAMES DARLING CEO; SHERWOOD TO RETIRE; 10/04/2018 – Anika Presenting at Deutsche Bank Health Care Conference May 8; 08/05/2018 – Anika to Showcase Commercial and Pipeline Portfolio at 18th Bi-Annual European Society for Sports Traumatology, Knee Surgery an

Anika Therapeutics, Inc., together with its subsidiaries, provides orthopedic medicines for patients with degenerative orthopedic diseases and traumatic conditions in the United States and internationally. The company has market cap of $447.49 million. The firm develops, makes, and commercializes therapeutic products based on its proprietary hyaluronic acid technology. It has a 24.05 P/E ratio. The Company’s orthobiologics products comprise ORTHOVISC, ORTHOVISC mini, MONOVISC, and CINGAL for the treatment of osteoarthritis of the knee; HYALOFAST, a biodegradable support for human bone marrow mesenchymal stem cells used for cartilage regeneration and as an adjunct for microfracture surgery; HYALONECT, a woven gauze used as a bone graft wrap; HYALOSS used to mix blood/bone grafts to form a paste for bone regeneration; and HYALOGLIDE, an ACP gel used in tenolysis treatment.

More notable recent Anika Therapeutics, Inc. (NASDAQ:ANIK) news were published by: Seekingalpha.com which released: “Premarket analyst action – healthcare” on June 20, 2018, also Seekingalpha.com with their article: “Anika Therapeutics’ CINGAL flunks late-stage knee osteoarthritis study; shares down 21% after hours” published on June 19, 2018, Fool.com published: “Why Pivotal Software, Anika Therapeutics, and Oracle Slumped Today” on June 20, 2018. More interesting news about Anika Therapeutics, Inc. (NASDAQ:ANIK) were released by: Nasdaq.com and their article: “2 Biotech Stocks That Tanked This Week: Can They Recover?” published on June 22, 2018 as well as Nasdaq.com‘s news article titled: “Mid-Afternoon Market Update: NASDAQ Rises 1%; Naked Brand Group Shares Spike Higher” with publication date: June 20, 2018.

Among 2 analysts covering Anika Therapeutics (NASDAQ:ANIK), 1 have Buy rating, 0 Sell and 1 Hold. Therefore 50% are positive. Anika Therapeutics had 4 analyst reports since January 24, 2018 according to SRatingsIntel. First Analysis downgraded Anika Therapeutics, Inc. (NASDAQ:ANIK) rating on Wednesday, June 20. First Analysis has “Hold” rating and $3400 target. The firm has “Market Perform” rating by Barrington Research given on Friday, February 23. The rating was upgraded by Barrington Research to “Outperform” on Friday, May 4. The firm earned “Overweight” rating on Wednesday, January 24 by First Analysis.

Investors sentiment decreased to 1.24 in 2018 Q1. Its down 0.13, from 1.37 in 2017Q4. It dived, as 16 investors sold Anika Therapeutics, Inc. shares while 42 reduced holdings. 21 funds opened positions while 51 raised stakes. 12.25 million shares or 0.12% less from 12.26 million shares in 2017Q4 were reported. Piermont Capital Mngmt invested in 0.72% or 43,324 shares. Gotham Asset Mngmt Limited Liability Company holds 0.02% of its portfolio in Anika Therapeutics, Inc. (NASDAQ:ANIK) for 31,335 shares. Spark Inv Management Lc holds 0.05% in Anika Therapeutics, Inc. (NASDAQ:ANIK) or 16,200 shares. Fisher Asset Mgmt Limited Liability holds 210,272 shares. Hl Financial Serv Limited Liability reported 0.01% stake. State Common Retirement Fund stated it has 0% in Anika Therapeutics, Inc. (NASDAQ:ANIK). Natixis Advisors Ltd Partnership owns 126,288 shares for 0.06% of their portfolio. Balyasny Asset Ltd Liability Corporation owns 4,800 shares or 0% of their US portfolio. Dimensional Fund Limited Partnership accumulated 930,771 shares or 0.02% of the stock. New England Management holds 4,200 shares. Zurcher Kantonalbank (Zurich Cantonalbank) invested in 0% or 957 shares. Prudential Financial Incorporated holds 25,150 shares or 0% of its portfolio. Citadel Advisors Lc stated it has 0% in Anika Therapeutics, Inc. (NASDAQ:ANIK). Eaton Vance Mgmt accumulated 5,732 shares. 38,700 are owned by First Manhattan Company.

Microsemi Corporation designs, manufactures, and markets analog and mixed-signal semiconductor solutions in the United States, Europe, and Asia. The company has market cap of $8.11 billion. The firm offers analog mixed-signal integrated circuits; field programmable gate arrays; system on chip solutions and application-specific integrated circuits; power management products; and timing and synchronization devices, and precise time solutions. It has a 39.55 P/E ratio. It also provides voice processing devices, radio frequency solutions, discrete components, enterprise storage and communication solutions, security technologies and scalable anti-tamper products, Ethernet solutions, and power-over-Ethernet integrated circuits and midspans, as well as custom design capabilities and services.

Investors sentiment decreased to 0.75 in Q1 2018. Its down 0.40, from 1.15 in 2017Q4. It fall, as 67 investors sold Microsemi Corporation shares while 103 reduced holdings. 64 funds opened positions while 64 raised stakes. 100.07 million shares or 9.94% less from 111.11 million shares in 2017Q4 were reported. Cqs Cayman Lp holds 26,500 shares. Focused Wealth Management reported 2 shares. Moreover, Zurcher Kantonalbank (Zurich Cantonalbank) has 0% invested in Microsemi Corporation (NASDAQ:MSCC). Chicago Equity Prtnrs Limited Liability Corp invested in 0.03% or 16,620 shares. Liberty Mutual Group Inc Asset holds 0.05% of its portfolio in Microsemi Corporation (NASDAQ:MSCC) for 23,160 shares. Moreover, Tokio Marine Asset Management has 1.31% invested in Microsemi Corporation (NASDAQ:MSCC) for 114,800 shares. Capstone Invest Advsr Ltd Company stated it has 338,287 shares. Victory Mgmt Incorporated holds 37,964 shares or 0.01% of its portfolio. Sei Investments holds 178,909 shares or 0.04% of its portfolio. Great West Life Assurance Can has 0.01% invested in Microsemi Corporation (NASDAQ:MSCC). Bnp Paribas Arbitrage reported 0% stake. Federated Invsts Pa stated it has 0.2% of its portfolio in Microsemi Corporation (NASDAQ:MSCC). Destination Wealth reported 23 shares or 0% of all its holdings. Atlantic Grp Ltd Liability holds 802 shares or 0% of its portfolio. Cetera Advsr Limited Co holds 4,800 shares.

More news for Microsemi Corporation (NASDAQ:MSCC) were recently published by: Gurufocus.com, which released: “6 Companies With High Business Predictability Ratings” on June 27, 2018. Streetinsider.com‘s article titled: “Goldman Sachs vice president charged with insider trading” and published on May 31, 2018 is yet another important article.

Anika Therapeutics, Inc. (NASDAQ:ANIK) Institutional Positions Chart